Events & Presentations Upcoming Events No upcoming events at this time Past Events Q1 2026 Earnings Call May 15, 2026 at 8:30 AM EDT Click here for webcast Investor Presentations ARS Pharma Corporate Presentation ARS Pharma Corporate Presentation 1.7 MB Aug 9, 2024 neffy® FDA Approval Call Supporting Materials neffy FDA Approval Call (August 2024) 5.9 MB Mar 7, 2024 at 1:00 PM EST Neffy® Investor Day To view the webcast, click here Supporting Materials neffy investor day presentation (Mar 2024) 10.1 MB Scientific Presentations ACAAI Poster 2025 Well-being & Anxiety Anxiety and well-being related to epinephrine nasal spray versus autoinjector in food allergic patients and caregivers (Greenhawt) 1.1 MB ACAAI Poster 2025 Stability Stability of epinephrine nasal spray under freeze, thaw and extreme temperatures (Golden) 570.7 KB ACAAI Poster 2025 neffy Survey Survey of patients who were prescribed epinephrine nasal spray (Rosenblum) 603.6 KB ACAAI Poster 2025 Sniff Effect of sniff after dosing of epinephrine nasal spray (Spergel) 471.5 KB ACAAI Poster 2025 Same Nostril Rationale for second dose of epinephrine nasal spray to the same nostril (Casale) 567.2 KB ACAAI Poster 2025 Eye Toxicity Low risk of ocular toxicity after unintentional exposure of epinephrine nasal spray (Ellis) 352.6 KB ACAAI Poster 2024 HF Packaging Successful Administration of neffy, Epinephrine Nasal Spray, When Provided with a Two-Dose Carrying Case– A Human Factor Study 1.2 MB ACAAI Poster 2024 BP Safety Cardiovascular Safety of Intramuscular and Intranasal Epinephrine Administration 831.2 KB ACAAI Poster 2024 EPI 18 Pharmacokinetics and Pharmacodynamics Following Repeat Dosing of neffy, Epinephrine Nasal Spray, Versus Intramuscular Injection During Induced Allergic Rhinitis 952.1 KB ACAAI Poster 2024 PK Profiles Significant Differences in Pharmacokinetic Profiles Among Epinephrine Products – What is the Mechanism for Efficacy? 579.6 KB Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
Investor Presentations ARS Pharma Corporate Presentation ARS Pharma Corporate Presentation 1.7 MB Aug 9, 2024 neffy® FDA Approval Call Supporting Materials neffy FDA Approval Call (August 2024) 5.9 MB Mar 7, 2024 at 1:00 PM EST Neffy® Investor Day To view the webcast, click here Supporting Materials neffy investor day presentation (Mar 2024) 10.1 MB Scientific Presentations ACAAI Poster 2025 Well-being & Anxiety Anxiety and well-being related to epinephrine nasal spray versus autoinjector in food allergic patients and caregivers (Greenhawt) 1.1 MB ACAAI Poster 2025 Stability Stability of epinephrine nasal spray under freeze, thaw and extreme temperatures (Golden) 570.7 KB ACAAI Poster 2025 neffy Survey Survey of patients who were prescribed epinephrine nasal spray (Rosenblum) 603.6 KB ACAAI Poster 2025 Sniff Effect of sniff after dosing of epinephrine nasal spray (Spergel) 471.5 KB ACAAI Poster 2025 Same Nostril Rationale for second dose of epinephrine nasal spray to the same nostril (Casale) 567.2 KB ACAAI Poster 2025 Eye Toxicity Low risk of ocular toxicity after unintentional exposure of epinephrine nasal spray (Ellis) 352.6 KB ACAAI Poster 2024 HF Packaging Successful Administration of neffy, Epinephrine Nasal Spray, When Provided with a Two-Dose Carrying Case– A Human Factor Study 1.2 MB ACAAI Poster 2024 BP Safety Cardiovascular Safety of Intramuscular and Intranasal Epinephrine Administration 831.2 KB ACAAI Poster 2024 EPI 18 Pharmacokinetics and Pharmacodynamics Following Repeat Dosing of neffy, Epinephrine Nasal Spray, Versus Intramuscular Injection During Induced Allergic Rhinitis 952.1 KB ACAAI Poster 2024 PK Profiles Significant Differences in Pharmacokinetic Profiles Among Epinephrine Products – What is the Mechanism for Efficacy? 579.6 KB Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
Anxiety and well-being related to epinephrine nasal spray versus autoinjector in food allergic patients and caregivers (Greenhawt) 1.1 MB
Successful Administration of neffy, Epinephrine Nasal Spray, When Provided with a Two-Dose Carrying Case– A Human Factor Study 1.2 MB
Pharmacokinetics and Pharmacodynamics Following Repeat Dosing of neffy, Epinephrine Nasal Spray, Versus Intramuscular Injection During Induced Allergic Rhinitis 952.1 KB
Significant Differences in Pharmacokinetic Profiles Among Epinephrine Products – What is the Mechanism for Efficacy? 579.6 KB
